U S Life Sciences Outlook 2025 Cbre U.s life sciences employment hit a record high in late 2024 and more job growth is expected in 2025. the life sciences industry remains in a period of unprecedented innovation and discovery. fda novel drug approvals in 2024 were the sixth highest annual total on record. A panel of cbre experts shared key findings from the u.s. life sciences outlook and u.s. life sciences quarterly figures and discussed the investment environment for the sector, including results from the u.s. investor intentions survey.
U S Life Sciences Outlook 2025 Cbre Many life sciences employers are adding employees, as total u.s. life sciences employment reached a record high in october 2024. various factors could dampen this improved outlook, including any negative impacts to consumer spending. U.s life sciences employment hit a record high in late 2024 and more job growth is expected in 2025. the life sciences industry remains in a period of unprecedented innovation and discovery. fda novel drug approvals in 2024 were the sixth highest annual total on record. The 2025 outlook report highlights five trends that will be good for life sciences real estate this year, including the improving u.s. economy, strong sector employment and slightly. Outlook for life sciences companies remains strong. thousands of treatments are being investi ated, and spending on pharmaceuticals remains high. although companies early in their discovery process aren’t getting financing as quickly as happened at the height of the market, overall venture capital funding was $5.6 billion higher last year than.
U S Life Sciences Outlook 2025 Cbre The 2025 outlook report highlights five trends that will be good for life sciences real estate this year, including the improving u.s. economy, strong sector employment and slightly. Outlook for life sciences companies remains strong. thousands of treatments are being investi ated, and spending on pharmaceuticals remains high. although companies early in their discovery process aren’t getting financing as quickly as happened at the height of the market, overall venture capital funding was $5.6 billion higher last year than. Looking at 2025, cbre and cushman & wakefield are forecasting continued funding flows to the sector with a potential “start of a cre recovery,” according to cushman & wakefield’s “life sciences funding in view: 2025 outlook” write up. Cbre's newly released 2025 u.s. life sciences outlook highlights continued growth driven by key factors such as an improving economy, robust sector employment, and a more favorable capital market environment. however, the industry faces potential challenges. Various drivers of life sciences industry expansion appear well entrenched, acting as a stabilizing force in the near term and a catalyst for long term growth. the number of drug clinical trials in the u.s. has stabilized to more normal levels since a surge in 2021 but remains elevated (figure 1). Looking ahead to 2025, both cbre and cushman & wakefield anticipate continued investment in the sector, with signs of a potential commercial real estate (cre) recovery, according to cushman & wakefield’s “life sciences funding in view: 2025 outlook” report.
Outlook Cbre Looking at 2025, cbre and cushman & wakefield are forecasting continued funding flows to the sector with a potential “start of a cre recovery,” according to cushman & wakefield’s “life sciences funding in view: 2025 outlook” write up. Cbre's newly released 2025 u.s. life sciences outlook highlights continued growth driven by key factors such as an improving economy, robust sector employment, and a more favorable capital market environment. however, the industry faces potential challenges. Various drivers of life sciences industry expansion appear well entrenched, acting as a stabilizing force in the near term and a catalyst for long term growth. the number of drug clinical trials in the u.s. has stabilized to more normal levels since a surge in 2021 but remains elevated (figure 1). Looking ahead to 2025, both cbre and cushman & wakefield anticipate continued investment in the sector, with signs of a potential commercial real estate (cre) recovery, according to cushman & wakefield’s “life sciences funding in view: 2025 outlook” report.
2024 U S Life Sciences Outlook Cbre Various drivers of life sciences industry expansion appear well entrenched, acting as a stabilizing force in the near term and a catalyst for long term growth. the number of drug clinical trials in the u.s. has stabilized to more normal levels since a surge in 2021 but remains elevated (figure 1). Looking ahead to 2025, both cbre and cushman & wakefield anticipate continued investment in the sector, with signs of a potential commercial real estate (cre) recovery, according to cushman & wakefield’s “life sciences funding in view: 2025 outlook” report.
2024 U S Life Sciences Outlook Cbre
Comments are closed.